Wall Street analyst estimates for Recursion Pharmaceuticals, Inc. (RXRX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $44.3M | $33.9M – $69.4M | -$0.90 | 5 |
| 2027E | $55.6M | $30.5M – $89.5M | -$0.87 | 5 |
Figures in USD · consensus as of November 3, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 6 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (−2 sell to +2 buy) | 0.40 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-03-03 | $-0.22 | ||
| 2026-11-02 | $-0.22 | $-0.22 | -0.5% |
| 2026-08-05 | $-0.25 | $-0.24 | -4.2% |
| 2026-05-06 | $-0.22 | $-0.30 | +26.7% |
| 2026-02-25 | $-0.21 | $-0.28 | +25.0% |
| 2025-11-05 | $-0.36 | $-0.38 | +5.3% |
| 2025-08-05 | $-0.41 | $-0.35 | -17.1% |
| 2025-05-05 | $-0.50 | $-0.44 | -13.6% |
Valuation Ratios
| Price / Book | 2.30 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $3.4M | $10.0M | $39.7M | $43.9M | $58.8M | $74.7M |
| Cost of Revenue | $45.8M | 0 | 0 | $48.3M | $42.6M | $45.2M | $121.0M |
| Gross Profit | -$44.1M | $3.4M | $10.0M | -$8.6M | $1.3M | $13.6M | -$46.3M |
| Research & Development | $45.8M | $63.3M | $135.3M | $155.7M | $241.2M | $314.4M | $425.3M |
| Selling, General & Admin | $19.0M | $25.3M | $57.7M | $81.6M | $110.8M | $178.2M | $176.6M |
| Operating Expenses | $64.2M | $88.0M | $192.8M | $237.1M | $351.3M | $492.6M | $601.9M |
| Operating Income | -$62.4M | -$84.6M | -$182.8M | -$245.7M | -$350.1M | -$479.0M | -$648.1M |
| EBITDA | -$59.4M | -$81.7M | -$175.1M | -$227.7M | -$307.6M | -$426.7M | -$559.4M |
| Interest Expense | $635,000 | $1.4M | $3.0M | $55,000 | $97,000 | $1.6M | $1.8M |
| Pre-tax Income | -$61.9M | -$87.0M | -$186.5M | -$239.5M | -$332.1M | -$464.8M | -$644.9M |
| Income Tax | 0 | 0 | 0 | 0 | -$4.1M | -$1.1M | -$136,000 |
| Net Income | -$62.5M | -$87.0M | -$186.5M | -$239.5M | -$328.1M | -$463.7M | -$644.8M |
| EPS | -$0.37 | -$0.52 | -$1.05 | -$1.36 | -$1.58 | -$1.69 | -$1.44 |
| EPS (Diluted) | -$0.37 | -$0.52 | -$1.05 | -$1.36 | -$1.58 | -$1.69 | -$1.44 |
| Shares Outstanding (Diluted) | 165.8 M | 165.8 M | 170.3 M | 175.5 M | 207.9 M | 274.2 M | 447.4 M |
Price
| Price | $3.83 (closing price, November 2, 2026) |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Related companies: DNLI · RLAY · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of RXRX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks